Peptide Industry Payment Trends & Reports

The peptide and research chemical market is growing - and the payment processing landscape is evolving with it. Card network rule changes, regulatory shifts, and new payment methods are reshaping how peptide merchants collect revenue. Staying informed is not optional.

How large is the peptide market and how fast is it growing in 2025?

The global peptide therapeutics market reached $48.3 billion in 2024 and is projected to grow at a compound annual growth rate of 9.4% through 2030, according to Grand View Research. Research-use peptide sales - the category covering BPC-157, TB-500, and similar compounds sold to research institutions and individual researchers - represent an estimated $2.1 billion subset of this market.

Domestic US peptide eCommerce grew approximately 22% year-over-year in 2024, driven by 3 factors: increased institutional research interest in peptide compounds, growing consumer awareness through longevity and biohacking communities, and expanding online distribution infrastructure. Payment processing volume processed through high-risk acquiring relationships for peptide merchants grew at a rate of 31% in the same period - indicating that more of the market is formalizing its payment infrastructure.

What regulatory changes are most likely to affect peptide payment processing in the next 12 to 24 months?

Three regulatory developments are actively being monitored by high-risk acquiring banks serving the peptide industry as of Q4 2025.

• FDA guidance on research chemicals: The FDA has issued informal guidance signals indicating increased scrutiny of "research use only" designations used to sell human-grade quantities of peptide compounds. A formal rulemaking process, if initiated, would take 18 to 36 months but could fundamentally alter the compliance landscape for US-based peptide merchants. Acquiring banks are pre-positioning by tightening underwriting for new peptide merchant applications.
• Visa and Mastercard MCC reclassification: Industry sources indicate that Visa is evaluating reclassification of certain peptide and research chemical merchants from MCC 5912 (drug stores) to a new high-risk research chemicals category that would carry stricter chargeback thresholds and enhanced due diligence requirements.
• State-level scheduling: Several states including Florida, Georgia, and Texas have introduced or are considering scheduling certain synthetic peptide analogs as controlled substances. State scheduling creates a patchwork compliance environment and can trigger acquiring bank terminations for merchants with significant customer volume in newly regulated states.

Which payment methods are gaining adoption fastest among peptide eCommerce stores?

ACH bank transfer adoption among peptide merchants grew 47% in 2024 as merchants sought lower-cost alternatives to credit card processing. Offering ACH at checkout with a 2% to 3% discount incentive converts approximately 25% to 35% of customers from card to bank transfer, reducing blended processing costs significantly.

Cryptocurrency payments represent a growing share of peptide merchant revenue, with approximately 8% to 12% of high-volume peptide stores now accepting USDC, Bitcoin, or Ethereum as primary or secondary payment methods. Crypto acceptance reduces chargeback exposure to zero (blockchain transactions are irreversible) but requires merchant education on wallet management and tax reporting.

Buy Now Pay Later (BNPL) integration is emerging in the peptide market, with average order values of $250 to $600 making installment options attractive to customers. BNPL conversion lift for peptide stores averages 15% to 25% for orders above $200, and chargeback risk is shifted to the BNPL provider rather than the merchant - making it a risk-reduction tool as well as a revenue driver.

How are high-risk acquiring banks changing their underwriting standards for peptide merchants in 2025?

Acquiring bank underwriting for peptide merchant accounts tightened significantly in 2024 and has continued into 2025 across 4 dimensions: required documentation volume, website compliance standards, volume cap conservatism, and reserve percentages for new merchants.

The average initial monthly volume cap for new peptide merchant accounts dropped from $75,000 in 2022 to $35,000 to $50,000 in 2025. Reserve percentages for new accounts increased from an average of 7% to an average of 9% to 12% at many acquiring relationships. Website compliance review - once a cursory check - now involves detailed scrutiny of checkout flow, terms language, product descriptions, and post-purchase email templates before account approval.

The implication for peptide merchants: a complete and compliant application package is more valuable than ever. Merchants who submit complete documentation, a compliant website, and a well-structured processing history (even from a previous account) are approved faster and at better rates than merchants who submit incomplete applications and negotiate documentation later.

What does the growth of alternative payment networks mean for peptide merchants long-term?

Real-time payment networks (RTP) operating outside traditional card network rails are emerging as a structural alternative to Visa and Mastercard for certain transaction types. The US Federal Reserve's FedNow network, launched in 2023, now covers approximately 1,200 financial institutions and supports instant bank-to-bank transfers at fractions of card processing costs.

For peptide merchants, alternative payment rails offer 3 long-term advantages: lower processing costs (RTP fees are flat, typically $0.01 to $0.10 per transaction versus percentage-based card fees), elimination of chargeback risk (bank transfers are pull transactions requiring mutual authentication), and reduced dependence on Visa/Mastercard rule changes that periodically affect high-risk merchants disproportionately.

The limitation is consumer adoption: only 15% to 20% of US consumers are currently enrolled in real-time payment systems that peptide merchants can accept. However, adoption is projected to reach 65% by 2027 as major banks complete FedNow integration. Peptide merchants who build multi-rail payment infrastructure now will be positioned advantageously as alternative payment methods achieve mainstream adoption.